tions or diseases causing bone marrow dysfunction [1] . Advanced human immunodeficiency virus (HIV) infection is often accompanied by impaired production of blood cell elements in bone marrow [2] . Various nucleoside analogue antiretrovirals and other medications used to treat the complications of HIV disease cause neutropenia [3] . GM-CSF is effective in these circumstances [4] and has also been shown to prevent bacterial and opportunistic infections in HIV-infected patients with CD4 + lymphocyte counts !100 cells/mm 3 [35] . There have been several clinical reports of beneficial effects of GM-CSF on plasma HIV-1 RNA levels and CD4 + lymphocyte counts in patients with HIV infection, particularly in patients with advanced HIV disease for whom antiretroviral therapy is not effectively controlling HIV replication [5] [6] [7] [8] . In vitro studies have had mixed results, with some showing enhancement [9, 10] and others showing inhibition [11] or no effect [12, 13] of GM-CSF on HIV replication in infected cells.
National Institute of Allergy and Infectious Diseases (NIAID) AIDS Clinical Trials Group (ACTG) Protocol 5041 was designed to determine, in a double-blind, placebo-controlled fashion, what effect GM-CSF had on CD4 + cell counts and HIV replication in a population of antiretroviral-treated patients who were medically stable but had incompletely controlled HIV replication.
PATIENTS AND METHODS

Study population.
We enrolled patients in the study if they met the following criteria: age у18 years; documented HIV infection; screening plasma HIV-1 RNA level у1500 copies/ mL that remained stable within a 0.7-log 10 copies/mL difference between the screening visit HIV-1 RNA level and the preentry visit HIV-1 RNA level (separated by at least 7 days); and receipt of a stable potent antiretroviral therapy regimen for a minimum of 8 weeks before study entry with the intent to continue this therapy through at least the first 16-week randomized phase of the study. Patients were excluded from the study if they had a hemoglobin concentration !9.1 g/dL for men and !8.9 g/dL for women; an absolute neutrophil count !750 cells/mm 3 ; a platelet count !50,000 platelets/mm 3 ; a serum bilirubin concentration 11.5 times the upper limit of normal (unless the patient was receiving indinavir); serum concentrations of hepatic aminotransferase or alkaline phosphatase 15 times the upper limit of normal; a serum creatinine concentration 12 times the upper limit of normal; a history of infection or other acute medical illness within 14 days before study entry; unexplained fever; chronic diarrhea; or malignancy other than minimal Kaposi sarcoma. Patients were also excluded if they had received systemic chemotherapy or radiation therapy for cancer treatment within 14 days before study entry; were pregnant or breast-feeding; had previously experienced an adverse reaction to yeast-derived rhu GM-CSF, other yeast-derived products, or any other component of the study drug; had significant cardiopulmonary disease; or had received any immunomodulating agents within 30 days before study entry.
Patients were recruited at 16 sites in the United States. The study was approved by the institutional review board of each medical center. Written informed consent was obtained from patients before enrollment in the study, and the human experimentation guidelines of the US Department of Health and Human Services and those of the authors' institutions were followed.
Study design. ACTG 5041 was a phase 2, multicenter, randomized, double-blind, placebo-controlled evaluation of GM-CSF, followed by open-label, long-term treatment. Patients were randomly assigned in step 1 to receive a 16-week course of either 250 mg of GM-CSF (Immunex) or placebo subcutaneously 3 times/week. Patients then received 250 mg of openlabel GM-CSF subcutaneously 3 times/week for 32 additional weeks (step 2). Baseline potent antiretroviral regimens were maintained through at least the first 16 weeks of the study. If this regimen changed, patients were withdrawn from the study. Administration of appropriate prophylaxis for opportunistic infections was permitted.
Adverse events and any new AIDS-defining events were graded according to NIAID criteria [14] . Dose reductions and temporary or permanent discontinuation of study medication were as specified in the protocol.
Evaluation of patients and follow-up. Clinical evaluations, safety laboratory tests, and plasma HIV-1 RNA levels and CD4 + and CD8 + lymphocyte measurements were done before study entry, at the time of entry, and at weeks 4, 8, 16, 20, 24, 32, 40 , and 48. Memory and naive lymphocyte subset analyses were performed before and at the time of study entry and at weeks 16 and 48.
Plasma HIV-1 RNA levels and CD4 + lymphocyte counts were monitored for all patients by the participating sites. A quantitative HIV-1 RNA assay (HIV-1 RNA Ultrasensitive Amplicor Monitor; Roche Diagnostics) with a lower limit of quantitation of 50 copies/mL was used. The assay was performed by a central laboratory (J.B.J.). Study treatment was discontinued for patients who experienced an increase in plasma HIV-1 RNA level of 11.0 log 10 copies/mL or a 50% decrease in CD4 + lymphocyte count from baseline on 2 consecutive determinations.
Immunologic assays. Lymphocyte phenotypes were examined in whole blood using ACTG consensus methods [15] and 2-and 3-color flow cytometry. Chemokine receptor density was calculated by flow cytometry, using phycoerythrin-conjugated QuantiBRITE bead standards (Becton Dickinson), and by converting fluorescence intensity to numbers of fluorochrome-labeled antibodies bound, as described elsewhere [16] . Lymphocyte proliferation responses were monitored using ACTG consensus methods [15] . b-chemokine levels in cryopreserved supernatants of peripheral blood mononuclear cells (PMBCs) cultured overnight with 5 mg/mL phytohemagglutinin (Sigma) or 0.1 mg/mL Escherichia coli lipopolysaccharide (Sigma) were measured by ELISA (R&D Systems).
Thymic output was evaluated from total PBMCs by mea-suring signal joint T cell receptor excision circles (TRECs), using real-time polymerase chain reaction (PCR 3 ) and the screening HIV-1 RNA level (1500-9999 vs. у10,000 copies/mL). The HIV-1 RNA stratification was for the purpose of balance only. The primary analysis of treatment effects on plasma HIV-1 RNA levels, however, was performed on the low and high CD4 + lymphocyte count strata separately. We assumed that patients with CD4 + cell counts 1200 cells/mm 3 would have primarily M-tropic, CCR5-using virus strains, whereas those with CD4 + cell counts !200 cells/ mm 3 would be more likely to have T-tropic, CXCR4-using strains. We wanted to see whether the virologic effects of GM-CSF would be different in the 2 groups of patients.
The primary virologic end point was an on-treatment analysis of the change in log 10 plasma HIV-1 RNA level from the average of the 2 baseline values (entry and preentry visits) to the week 16 evaluation, using the last value carried forward for subjects who missed the week 16 evaluation. Although all 116 subjects started study treatment, 6 did not have a follow-up evaluation after receiving blinded study treatment and were excluded from the primary and other "as treated" secondary analyses. Significance at the 5% level required a P value !.04884 to adjust for an interim analysis of the virologic end point (with a null result), using the O'Brien-Fleming stopping boundary [17] .
One secondary virologic analysis was an on-treatment analysis based on baseline and week 16 evaluations; subjects who were missing the week 16 evaluation were excluded from this analysis. In addition, an intent-to-treat virologic analysis was performed that included all randomized subjects and in which the last value carried forward was used for subjects missing the week 16 evaluation. Other secondary end points, analyzed "as treated," included the changes in CD4 + and CD8 + lymphocyte counts, naive and memory lymphocyte subpopulations, activation markers on CD4 + and CD8 + cells, CCR5 and CXCR4 receptors on CD4 + cells, circulating dendritic cell counts, enumerations of cells with TRECs, and lymphoproliferative responses to recall antigens. The secondary analyses were exploratory, without a well-defined type I error; corresponding tests in which P was р.05 are reported here as statistically significant for exploratory purposes only.
Tests of a treatment effect were 2-sided. Separate tests within each CD4
+ cell count stratum were stratified on the HIV-1 RNA level stratification factor. Tests on the combined CD4 + cell count strata were stratified on both the HIV-1 RNA level and CD4 + cell count factors. For the HIV-1 RNA end point, a rank test for left-censored observations (to adjust for values censored by the lower limit of quantification of the assay) was used, with Wilcoxon weights, by means of Proc-Lifetest (SAS Institute). Other continuous end points were tested with an exact WilcoxonMann-Whitney test, using Proc-StatXact for SAS Users (version 4.0.1; Cytel) on a SUN Solaris system. Ninety-five percent confidence intervals on shift parameters were based on inversions of the corresponding hypothesis tests. Dichotomous toxicity outcomes were tested with exact tests, first of homogeneity of the odds ratio across strata, with Zelen's exact homogeneity test [18] , and then, when appropriate, of the null hypothesis that the common odds ratio is unity [19] , using Proc-StatXact. The sign test was used to test a change from baseline in HIV-1 RNA level and CD4 + cell count in subjects receiving GM-CSF, by means of Proc-StatXact.
RESULTS
Study population.
Between November 1999 and October 2000, 116 patients were enrolled: 62 patients with CD4 + lymphocyte counts у200 cells/mm 3 and 54 with CD4 + lymphocyte counts !200 cells/mm 3 . Six patients were excluded from the analysis because they did not have an on-treatment evaluation during the blinded, randomized phase of the study. Five of these 6 subjects were from the GM-CSF group (1 was in the higher CD4 + cell count stratum, and 4 were in the lower CD4 + cell count stratum). Three of these 5 subjects discontinued treatment because of toxicity, 1 discontinued treatment because of an acute allergic reaction, and 1 was unwilling to self-inject the medication. The only subject to discontinue study treatment in the placebo group died of Pneumocystis carinii pneumonia. In both strata, the subjects in the 2 treatment groups had similar baseline characteristics (table 1) . Virologic data. In the у200 and !200 CD4 + cells/mm 
The baseline CD4 + cell count is the average of the counts at preentry evaluation and entry evaluation. The baseline plasma HIV-1 RNA level is the average of the levels at preentry evaluation and entry evaluation, if these levels differed by р0.7 log 10 copies/mL; otherwise, the level at entry evaluation was used. GM-CSF, granulocyte-macrophage colony-stimulating factor; HIV-1, human immunodeficiency virus type 1; Q1, first quartile; Q3, third quartile. + cell count strata combined found the change in plasma HIV-1 RNA level in the GM-CSF group to be +0.048 log 10 copies/mL, compared with Ϫ0.103 log 10 copies/mL in the placebo group (  ; table 2 ). P p .036 One secondary virologic analysis was based on baseline and week 16 evaluations and excluded 11 subjects who were missing the week 16 evaluation. The differences between treatment + T lymphocyte count (B), and CD8 + T lymphocyte count (C) among subjects initially randomized to receive granulocyte-macrophage colonystimulating factor (GM-CSF) or placebo. Week 0 was the time of initial randomization to GM-CSF or placebo. Subjects initially randomized to placebo began receiving an open-label GM-CSF regimen at week 16. For the blinded phase, baseline data are the mean of preentry and entry data, and week 16 data are from the last evaluation at which the patient was receiving the initial antiretroviral regimen and blinded, randomly assigned medication. For the open-label phase and time points marked "initially randomized to GM-CSF," baseline data are the mean of preentry and entry data, and week 32 and 48 data are from evaluations at those time points. Only data for subjects who were receiving steady antiretroviral and GM-CSF regimens were included. For the open-label phase and time points marked "initially randomized to placebo," baseline data are from the last evaluation before subjects began receiving open-label GM-CSF, and week 32 and 48 data are from evaluations at those time points. Only subjects who were receiving steady antiretroviral and open-label GM-CSF regimens were included. Note that this group of subjects had only received GM-CSF for 16 and 32 weeks at weeks 32 and 48, respectively. n, no. of subjects initially randomized to receive GM-CSF or placebo who were available for follow-up at a particular study week. ). (When the 2 strata were combined, the P p .202 median changes were +0.048 and Ϫ0.063 log 10 copies/mL, respectively;
.) P p .067 Another secondary virologic analysis was an intent-to-treat analysis that included all 116 randomized subjects. In this analysis, we used the last evaluation carried forward for subjects who missed the week 16 evaluation. The differences between treatment groups (GM-CSF vs. placebo) in changes from baseline to week 16 in plasma HIV-1 RNA levels were not significant for subjects with baseline CD4 + cell counts !200 cells/mm 3 (median change, Ϫ0.014 vs. Ϫ0.064 log 10 copies/mL; P p ) or subjects with CD4 + cell counts у200 cells/mm 3 (+0.184 .163 vs. Ϫ0.077 log 10 copies/mL; ). (When the 2 strata were P p .084 combined, the median changes were +0.069 and Ϫ0.066 log 10 copies/mL, respectively;
.) P p .027 Immunologic data. During the initial, 16-week, randomized phase of our study, there were trends toward increases in CD4 + lymphocyte counts with GM-CSF treatment (median change, +29 vs. Ϫ8 cells/mm 3 + cell count changes were +1 and Ϫ4 cells/mm 3 for the GM-CSF group and the placebo group, respectively (P p ), and the median naive CD8 + cell count changes were +1 .034 and Ϫ27 cells/mm 3 ( ). There were no significant dif-P p .091 ferences between treatment groups in changes in naive cell subpopulations in the у200 CD4 + cells/mm 3 stratum or in changes of memory CD4 + and CD8 + cell subpopulations in either CD4 + cell count stratum. When CD4 + cell count strata were combined, the median change in peripheral blood TREC content from baseline to week 16 was +709 copies/mg of PBMC DNA in the GM-CSF arm and +134 copies/mg of PBMC DNA in the placebo arm ( ). P p . 22 The median baseline levels were 2431 copies/mg of PBMC DNA for the GM-CSF group and 1920 copies/mg of PBMC DNA for the placebo group.
GM-CSF had the expected effect of increasing absolute neutrophil counts in study subjects. In the higher CD4 + cell count stratum, median neutrophil counts increased by 645 neutrophils/mm 3 at week 16 in the GM-CSF group and decreased by 189 neutrophils/mm 3 in the placebo group ( ). In the P p .0032 lower CD4 + cell count stratum, median neutrophil counts increased by 433 neutrophils/mm 3 in the GM-CSF group and remained the same in the placebo group ( ). Median P p .0028 monocyte counts did not change significantly.
We observed no effects of GM-CSF treatment on the expression of activation markers on CD4 + or CD8 + lymphocytes. There were no effects of treatment on density of CCR5 or CXCR4 on either CD4 + T cells or CD14 + monocytes. Except for a marginally significant decrease in lipopolysaccharideinduced expression of RANTES after 16 weeks of treatment with GM-CSF (Ϫ603 pg/mL, vs. 0 pg/mL in the placebo group; ), there were no differences between the groups in levels P ! .04 of b-chemokines expressed in vitro in response to phytohemagglutinin or lipopolysaccharide. The number of circulating myeloid and lymphoid dendritic cells did not change. Lymphoproliferative responses to cytomegalovirus, pokeweed mitogen, Candida antigen, and tetanus toxoid were unaffected by treatment.
Overall, including those who were initially randomized to receive placebo, 71 subjects received a steady antiretroviral regimen and had CD4 + cell counts measured after 16 weeks of GM-CSF treatment; 38 received a steady antiretroviral regimen and had CD4 + cell counts measured after 32 weeks; and 13 received a steady antiretroviral regimen and had CD4 + cell counts measured after 48 weeks. Although we recognize the potential bias of this analysis (e.g., the 13 subjects analyzed at 48 weeks tended to have slightly lower plasma HIV-1 RNA levels than the other subjects at baseline [3.768 vs. 4.254 log 10 copies/mL; ]), nonetheless, there was a steady increase P p .16 in median CD4 + cell counts over time for these GM-CSFtreated patients ( figure 1 and table 4) . The increase in median CD8 + cell count also was greater at 48 weeks than at 16 weeks ( figure 1 and table 4) .
Sixty-four, 35, and 11 subjects had naive and memory cell subsets measured at weeks 16, 32, and 48, respectively. There tended to be increases over time in both naive and memory CD4 + and CD8 + cell counts, more so in the naive CD8 + and memory CD4
+ and CD8 + cell subpopulations (table 5) . Clinical events. During the initial, 16-week, randomized phase, the only death was in the placebo group. The cause was P. carinii pneumonia (which occurred despite administration of atovaquone prophylaxis). Two other patients randomized to receive placebo developed esophageal candidiasis, and 1 of those also had toxoplasmic encephalitis; 2 had herpes simplex virus infections; and 1 developed non-Hodgkin lymphoma. In the GM-CSF group, 1 patient developed herpes simplex virus infection, and 1 had pelvic inflammatory disease. Thus, excluding the cases of herpes simplex virus infection and pelvic inflammatory disease, there tended to be fewer patients with AIDS-related clinical events (0 vs. 4) with GM-CSF treatment ( ). P p .1205 Adverse events. During the randomized, blinded phase of 
NOTE.
All results are based only on evaluations made while the subject was receiving a steady antiretroviral regimen. The baseline value is the average of the values at preentry and entry evaluations, for subjects initially randomized to GM-CSF, and the value at the last evaluation before initiation of open-label GM-CSF treatment, for subjects initially randomized to placebo. Data were available for 71 subjects at week 16, for 38 at week 32, and for 13 at week 48. Q1, first quartile; Q3, third quartile.
a "Study week" refers to the no. of weeks in which the subject had received
either blinded or open-label GM-CSF. b Calculated using the sign test. 
All results are based only on evaluations made while the subject was receiving a steady antiretroviral regimen. The baseline value is the average of the values at preentry and entry evaluations, for subjects initially randomized to GM-CSF, and the value at the last evaluation before initiation of open-label GM-CSF treatment, for subjects initially randomized to placebo. Data were available for 64 subjects at week 16, for 35 at week 32, and for 11 at week 48. Q1, first quartile; Q3, third quartile.
either blinded or open-label GM-CSF. b Calculated using the sign test.
the study, 4 patients in the GM-CSF group discontinued study medication because of toxic effects of treatment. Although it was uncommon, more patients assigned to receive GM-CSF experienced grade 3 (severe) or 4 (life-threatening) signs or symptoms judged to be at least possibly related to study drug than did patients assigned to placebo (12 patients in the GM-CSF group vs. 4 in the placebo group; ). The most P p .0327 frequent grade 3 or 4 adverse events in the GM-CSF group were local pain, swelling, or erythema (6 patients); fatigue (3 patients); and rash (2 patients). Other adverse events in the GM-CSF group included gastrointestinal symptoms (1 patient), chills and sweats (1 patient), and thrombocytopenia (1 patient). In the placebo group, the adverse events included hypertriglyceridemia (2 patients); local pain, swelling, or erythema (1 patient); gastrointestinal symptoms (1 patient); and mental status changes (1 patient). Thus, the occasional adverse events in the study in persons receiving GM-CSF treatment consisted primarily of local and systemic reactions to the injections.
DISCUSSION
This study did not find that GM-CSF has an antiviral effect, as has been reported elsewhere [5, 7, 8] . In fact, the administration of GM-CSF led to a small median increase (∼0.15 log 10 copies/mL) in plasma HIV-1 RNA levels in patients who had uncontrolled viral replication before administration of GM- When the naive and memory CD4 + cell changes were evaluated, a significant difference between the treatment groups was seen only in naive CD4 + lymphocyte counts in the !200 CD4 + cells/mm 3 stratum. Furthermore, nonsignificant trends toward increases in the fraction of lymphocytes that were recent thymic emigrants were associated with GM-CSF administration. This suggests that, in some patients, the increases in lymphocyte numbers during GM-CSF treatment may have been the result of enhanced production in the bone marrow, increased delivery of precursor cells to the thymus, and a greater output of new cells from the thymus. GM-CSF is not known to have direct effects on the thymus or on extrathymic sites of thymopoiesis. Nev-ertheless, we cannot exclude the possibility that GM-CSF may have induced redistribution of T lymphocytes from lymphoid organs into peripheral blood in a mechanism responsible for the increase in peripheral blood T lymphocytes.
As might be expected to result from the indirect effects of GM-CSF that have been proposed, the magnitude of the effect of GM-CSF on CD4 + lymphocyte counts appeared to increase modestly over time. It should be noted, however, that patients were allowed to change antiretroviral therapy after the first 16 weeks of the study, and this provision of the protocol limits our ability to draw conclusions from analysis of the second, open-label phase of the study. The long-term analysis, for which data were censored after antiretroviral regimens were changed, could have selected for subjects who were already experiencing increases in CD4 + cell counts. In addition, the number of subjects remaining for this analysis was small, and there was, of course, no placebo control group. Thus, selection bias or perhaps even an effect of continued antiretroviral treatment on immune reconstitution could be responsible for this increase.
Previous clinical studies have had mixed results with regard to the effects of GM-CSF on HIV levels and CD4 + cell counts. In a study by Scadden et al. [20] , the administration of 3 different doses of GM-CSF over the course of 28 days to 12 HIV-infected individuals receiving stable doses of zidovudine resulted in no changes in plasma HIV levels or CD4 + cell counts. Plasma HIV RNA levels did not change significantly in 13 HIVinfected persons receiving stable antiretroviral regimens who were treated by Bernstein et al. [6] with 5 mg/kg GM-CSF daily for 90 days. However, CD4
+ cell counts increased in 7 of 11 patients who completed therapy. Skowron et al. [7] randomized 20 patients receiving stable potent antiretroviral regimens to receive either GM-CSF (250 mg 3 times/week) or placebo for 8 weeks. More GM-CSF-treated patients than placebo recipients experienced decreases of у0.5 log 10 copies/mL in plasma HIV-1 RNA levels and increases of 130% in CD4 + cell counts between baseline and at least 1 time point, but the trend was not statistically significant.
In a Brazilian study, 105 HIV-infected patients with CD4 + cell counts !300 cells/mm 3 were randomized to receive either 125 mg/m 2 of GM-CSF or placebo twice weekly for 6 months [8] . Subjects were receiving antiretroviral regimens containing only nucleoside analogues, which changed as new drugs became available. Median plasma HIV-1 RNA levels decreased significantly (compared with the median change in the placebo group) in the GM-CSF group. There was a nonsignificant trend toward a 30-60-cell median increase in CD4 + lymphocyte counts among the treated patients.
Angel et al. [5] conducted a randomized, double-blind, placebo-controlled study of GM-CSF (250 mg 3 times/week) in 309 patients with advanced HIV disease. The primary end point was the occurrence of clinical events. The background and antiretroviral therapy were the community standard of care, and these could be changed by the treating physician as warranted. CD4 + cell counts were noted to increase in patients who received GM-CSF. Changes in virus load were not significantly different between groups, but, for patients who had plasma HIV-1 RNA levels below the limit of detection at study entry, viral suppression was maintained longer in the GM-CSF group. Fewer infections overall occurred in the GM-CSF group, but the number of opportunistic infections was not reduced by GM-CSF treatment. In our study, we found a trend toward fewer AIDS-related clinical events.
Our study is, to our knowledge, the only large randomized, placebo-controlled trial in which patients received stable potent antiretroviral regimens and in which an effect on HIV-1 RNA levels was the primary end point. When evaluated directly in this manner, GM-CSF appeared to have no effect in reducing HIV replication. In fact, there was a modest and significant effect in the opposite direction. Unlike other randomized studies of GM-CSF, ACTG 5041 required that subjects had remained virologically stable before enrollment within a difference of 0.7 log 10 copies/mL between the screening visit HIV-1 RNA level and the preentry visit HIV-1 RNA level. This requirement reduced potential bias that could have been introduced if patients who still had downward trends in plasma HIV-1 RNA levels as an effect of antiretroviral therapy were overrepresented in one group.
Laboratory findings supporting a putative mechanism for anti-HIV activity of GM-CSF were reported by Di Marzio et al. [21] , who showed that GM-CSF reduced chemokine coreceptor expression on blood monocytes and increased bchemokine excretion from these cells. Monocyte-derived macrophages treated with GM-CSF were less permissive of M-tropic HIV-1 replication than were untreated cells [21] . On the other hand, Wang et al. [22] found that GM-CSF increased surface expression of CCR5 on monocyte-derived macrophages and increased the extent of HIV-1 entry and replication. In a study by Lee et al. [23] , CCR5 expression was increased and CXCR4 expression was reduced in monocyte-derived macrophages treated with GM-CSF.
In contrast to these reports, our in vivo study found that treatment with GM-CSF had no significant effect on the expression of chemokine receptors on CD4 + lymphocytes or CD14 + monocytes. We do not understand the mechanism of the modest increase in plasma HIV-1 RNA level that was seen in association with GM-CSF treatment. It is conceivable that this was the result of a direct effect of GM-CSF on monocytes and/or macrophages that promoted viral replication in these cells. Alternatively, GM-CSF may have an effect on the chemokine receptors of tissue macrophages that harbor HIV and not on the monocytes that were available for sampling and analysis in this study. Finally, GM-CSF-induced up-regulation of tumor necrosis factor-a expression may have led to increased HIV replication [24, 25] .
In summary, GM-CSF does not have an antiviral effect in patients with ongoing HIV replication and may actually increase plasma HIV-1 RNA levels modestly. Nevertheless, there is some evidence that CD4 + lymphocyte counts also increase with GM-CSF administration and that these increases may become more substantial over time. After 16 weeks of treatment, the effects on plasma HIV-1 RNA levels and CD4 + lymphocyte counts were probably not clinically significant. In addition, the hypothesis that GM-CSF may have benefit in the prevention of opportunistic infections in patients with advanced disease is strengthened, although not supported definitively.
The effect of GM-CSF on CD4 + lymphocyte counts may be greater in patients with better viral suppression. Thus, the use of GM-CSF should be examined in persons who experience a good antiviral response to antiretrovirals but an inadequate CD4 + cell increase. GM-CSF, if administered over an extended period of time, could prove to have a clinically meaningful effect on CD4 + lymphocyte counts. Should the large clinical end-point studies currently being performed with interleukin-2 in this patient population show that the CD4 + cell count increases related to cytokine administration are clinically relevant, then that would argue favorably for the potential usefulness of a better-tolerated agent, such as GM-CSF. Clinical studies would be needed to evaluate this.
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